Impact of different therapeutic regimens on the outcome of patients with Crohn's disease of the upper gastrointestinal tract

被引:30
作者
Miehsler, W
Püspök, A
Oberhuber, G
Vogelsang, H
机构
[1] Univ Vienna, Dept Internal Med 4, Div Gastroenterol & Hepatol, A-1090 Vienna, Austria
[2] Univ Vienna, Dept Clin Pathol, A-1090 Vienna, Austria
关键词
Crohn's disease; gastroduodenum; permeability; therapy; proton pump inhibitor; mesalamine; prednisolone; azathioprine;
D O I
10.1097/00054725-200105000-00004
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
Background: To follow-up clinical and biochemical features in patients with Crohn's disease (CD) of the upper gastrointestinal (GI) tract and to evaluate the impact of different therapeutics on the outcome of these patients. Methods: 32 CD patients with endoscopically and histologically proven CD of the upper GI tract were included into this retrospective study. Gastroduodenal and intestinal permeability rests, inflammatory parameters, Crohn's Disease Activity Index (CDAI), and upper gastrointestinal complaint profile were sequentially assessed. These parameters were assessed at the beginning and followed up during therapies with antisecretory drugs, mesalamine, prednisolone, and azathioprine. Results: Symptoms responded to antisecretory drugs. Gastroduodenal permeability increased under mesalamine. Gastroduodenal and intestinal permeability as well as CDAI decreased under prednisolone. Under azathioprine, gastroduodenal and intestinal permeability. CDAI, and C-reactive protein decreased.
引用
收藏
页码:99 / 105
页数:7
相关论文
共 41 条
[11]   CLINICAL-FEATURES OF GASTRODUODENAL CROHNS-DISEASE IN ADOLESCENTS [J].
GRIFFITHS, AM ;
ALEMAYEHU, E ;
SHERMAN, P .
JOURNAL OF PEDIATRIC GASTROENTEROLOGY AND NUTRITION, 1989, 8 (02) :166-171
[12]  
HAGGITT RC, 1973, AM J CLIN PATHOL, V59, P613
[13]   High frequency of helicobacter negative gastritis in patients with Crohn's disease [J].
Halme, L ;
Karkkainen, P ;
Rautelin, H ;
Kosunen, TU ;
Sipponen, P .
GUT, 1996, 38 (03) :379-383
[14]   Medical therapy of active Crohn's disease [J].
Jarnerot, G ;
Sandberg-Gertzen, H ;
Tysk, C .
BAILLIERES CLINICAL GASTROENTEROLOGY, 1998, 12 (01) :73-92
[15]  
KORELITZ BI, 1981, AM J GASTROENTEROL, V76, P103
[16]  
KORELITZ BI, 1993, AM J GASTROENTEROL, V88, P1198
[17]  
LAROUCHE J, 1995, ALIMENT PHARM THERAP, V9, P315
[18]   DELIVERY AND FATE OF ORAL MESALAMINE MICROGRANULES WITHIN THE HUMAN SMALL-INTESTINE [J].
LAYER, PH ;
GOEBELL, H ;
KELLER, J ;
DIGNASS, A ;
KLOTZ, U .
GASTROENTEROLOGY, 1995, 108 (05) :1427-1433
[19]  
LOSSING A, 1983, CAN J SURG, V26, P358
[20]   SUCROSE - A NOVEL PERMEABILITY MARKER FOR GASTRODUODENAL DISEASE [J].
MEDDINGS, JB ;
SUTHERLAND, LR ;
BYLES, NI ;
WALLACE, JL .
GASTROENTEROLOGY, 1993, 104 (06) :1619-1626